Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Trial Profile

Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Jan 2018

At a glance

  • Drugs Carfilzomib (Primary) ; Cytarabine; Dexamethasone; Hydrocortisone; Methotrexate; Mitoxantrone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 06 Jan 2018 The study has been suspended in Italy.
    • 07 Nov 2017 Status changed from suspended to recruiting.
    • 26 Oct 2017 This study is recruiting in Denmark and is suspended in Austria.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top